title: Prognosis and gene expression profiling of 20q13-amplified breast cancers.
abstract: OBJECTIVE
  Amplification of chromosomal region 20q13 occurs in breast cancer but remains poorly characterized.
  
  
  METHODS
  To establish the frequency of 20q13 amplification and select the amplified cases to be studied, we used fluorescence in situ hybridization of bacterial artificial chromosome probes for three 20q13 loci (MYBL2, STK6, ZNF217) on sections of tissue microarrays containing 466 primary carcinoma samples. We used Affymetryx whole-genome DNA microarrays to establish the gene expression profiles of 20q13-amplified tumors and quantitative reverse transcription-PCR to validate the results.
  
  
  RESULTS
  We found 36 (8%) 20q13-amplified samples. They were distributed in two types: type 1 tumors showed ZNF217 amplification only, whereas type 2 tumors showed amplification at two or three loci. Examination of the histoclinical features of the amplified tumors showed two strikingly opposite data. First, type 1 tumors were more frequently lymph node-negative tumors but were paradoxically associated with a poor prognosis. Second, type 2 tumors were more frequently lymph node-positive tumors but were paradoxically associated with a good prognosis. Type 1 and type 2 showed different gene expression profiles. No 20q13 gene could be associated with type 1 amplification, whereas several 20q13 genes were overexpressed in type 2 tumors.
  
  
  CONCLUSIONS
  Our results suggest that amplified tumors of types 1 and 2 are two distinct entities resulting from two different mechanisms and associated to different prognosis.
authors.affiliation: Laboratoire d'Oncologie Moléculaire, Centre de Recherche en Cancérologie de Marseille, UMR599 Inserm, Marseilles, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Ginestier
authors.forename: Nathalie
authors.initials: N
authors.lastname: Cervera
authors.forename: Pascal
authors.initials: P
authors.lastname: Finetti
authors.forename: Séverine
authors.initials: S
authors.lastname: Esteyries
authors.forename: Benjamin
authors.initials: B
authors.lastname: Esterni
authors.forename: José
authors.initials: J
authors.lastname: Adélaïde
authors.forename: Luc
authors.initials: L
authors.lastname: Xerri
authors.forename: Patrice
authors.initials: P
authors.lastname: Viens
authors.forename: Jocelyne
authors.initials: J
authors.lastname: Jacquemier
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Charafe-Jauffret
authors.forename: Max
authors.initials: M
authors.lastname: Chaffanet
authors.forename: Daniel
authors.initials: D
authors.lastname: Birnbaum
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
mesh_terms: D001943:Breast Neoplasms / Q000235:genetics* / Q000601:surgery; D002890:Chromosomes, Human, Pair 20 / Q000235:genetics*; D016000:Cluster Analysis; D005260:Female; D005784:Gene Amplification; D020869:Gene Expression Profiling; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D015996:Survival Rate; D046888:Tissue Array Analysis / Q000379:methods; D016896:Treatment Outcome